Merck's Q2 2015 earnings call highlights strong performance in key areas, particularly the continued success of KEYTRUDA.  Positive guidance updates and management's focus on the pipeline, including the FDA acceptance of supplemental BLAs for KEYTRUDA, suggest a positive short-term outlook.  The call also discusses efforts to address competition and pricing pressures in some areas.
[1]
